Telix Pharmaceuticals Appointed Dr. Bernard Lambert as President of Telix Pharmaceuticals (US) Inc.
News,
Telix has today announced the appointment of Dr. Bernard Lambert as President and Chief Operating Officer (COO) of Telix’s US…
Read moreNews & Views
Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering
Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised…
Read more
Telix Pharmaceuticals and AMNI Partner for Prostate Cancer Imaging
Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA…
Read more
Telix Pharmaceuticals Launches $50M Underwritten Initial Public Offering
Telix Pharmaceuticals Limited is pleased to announce the opening of its Initial Public Offering to raise A$50…
Read more
Telix and University of Melbourne Establish Cancer Translational Research Partnership
Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of…
Read more
Telix Pharmaceuticals files $50M Underwritten Initial Public Offering
Telix Pharmaceuticals is pleased to announce it has filed a $50 million Underwritten Initial Public…
Read more
Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
Telix is pleased to announce the conclusion of collaboration and licensing agreement with CellSight Technologies, Inc. (CellSight) for the VisAcT immunoPET imaging technology…
Read more
Kevin McCann and Mark Nelson Appointed to the Board of Directors of Telix
News,
Telix is pleased to announce today that Mr. Kevin McCann AM and Dr. Mark Nelson have been appointed to the Board of Telix Pharmaceuticals Limited as Non-Executive…
Read more
Telix and Cyclotek Conclude Radiopharmaceutical Manufacturing Agreement for Australia and New Zealand
Telix is pleased to announce the completion of a Master Services Agreement with Cyclotek (Aust) Pty Ltd…
Read more
Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies
Telix is pleased to announce a licence agreement collaboration with Abzena plc (Abzena) for its prostate-specific membrane antigen antibodies…
Read more